Biotech

All Articles

AstraZeneca messages data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early look at the functionality of its own internal antib...

iTeos- GSK's TIGIT star shows relevant renovation

.After revealing a phase 3 launch based upon positive midstage end results, iTeos as well as GSK are...

More collaborative FDA can increase unusual ailment R&ampD: document

.The FDA should be actually extra available and also collective to unleash a surge in commendations ...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an unusually occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX as we...

Atea's COVID antiviral stops working to stop hospital stays in period 3

.Atea Pharmaceuticals' antiviral has stopped working another COVID-19 test, yet the biotech still ke...

Neurocrine's proposal to save mental illness prospect falls short

.Neurocrine Biosciences' schizophrenia program pivot has neglected. The biotech was actually not abl...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually made an overdue entrance to the radioligand event, paying out 100 thousand euro...

F 2G brings up $100M for 2nd try to acquire new antifungal to market

.After F2G's 1st effort to get a new class of antifungal to market was wrecked by the FDA, the U.K.-...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans in the middle of productivity tensions

.Moderna has pledged to cut R&ampD investing by $1.1 billion by 2027. The decision to shrink the bud...

Sanofi's $80M bet on Key dystrophy drug ends in phase 3 crash

.Merely four months after Sanofi wager $80 thousand in beforehand cash money on Key Therapies' losma...